To exclude excessive increase of unspecific lysis by CD19-specific CARTs in the presence of PipFcB, cytotoxicity against CD19− multiple myeloma cells (RPMI-8226) was evaluated. This evidence concerns the gene CD19 and plasma cell myeloma.